

Annalisa Perna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6824990/annalisa-perna-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

10,269
citations

45
h-index

101
g-index

108
ext. papers

11,813
ext. citations

12.3
avg, IF

5.19
L-index

#	Paper	IF	Citations
106	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial).. <i>Diabetes Research and Clinical Practice</i> , 2022 , 185, 109804	7.4	0
105	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	0
104	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2021 , 59, 309	3.9	0
103	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 575-587	6.9	0
102	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , 2021 , 18, e1003668	11.6	4
101	Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , 2021 , 18, e1003691	11.6	2
100	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , 2021 , 145, 137-149	3.3	1
99	Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria. <i>Journal of Investigative Medicine</i> , 2021 , 69, 1035-1043	2.9	1
98	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.. <i>PLoS ONE</i> , 2021 , 16, e0261113	3.7	4
97	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. <i>Frontiers in Genetics</i> , 2019 , 10, 681	4.5	7
96	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 338-350	7.4	11
95	An ExVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 56-72	7.4	36
94	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 224-238	7.4	22
93	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019 , 16, e1002777	11.6	21
92	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1177-1190	6.7	9
91	Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Gene Transfer. <i>Antioxidants and Redox Signaling</i> , 2019 , 31, 1255-1271	8.4	33
90	Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018 , 2, 420-436	0.4	17

89	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1414-1427	0.9	71
88	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 27-40	18.1	20
87	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 283-294	12.7	48
86	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. <i>Nephron</i> , 2018 , 140, 1-8	3.3	13
85	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2729-2737	12.7	69
84	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. <i>American Journal of Transplantation</i> , 2017 , 17, 3159-3171	8.7	38
83	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. <i>Diabetes</i> , 2017 , 66, 75-86	0.9	43
82	B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 1811-22	12.7	100
81	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1022-1030.e4	6.9	33
80	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 785-94	6.9	26
79	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. <i>The Lancet Global Health</i> , 2016 , 4, e307-19	13.6	195
78	Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet</i> , 2016 , 388, 2629-2641	40.1	127
77	Paricalcitol for secondary hyperparathyroidism in renal transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1205-14	12.7	44
76	A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. <i>Nephron</i> , 2015 , 130, 13-20	3.3	9
75	Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. <i>Blood</i> , 2014 , 123, 822-8	2.2	112
74	Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). <i>Systematic Reviews</i> , 2014 , 3, 69	3	19
73	Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 475-6	2.4	22
72	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. <i>The Cochrane Library</i> , 2014 , CD004293	5.2	29

71	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2013 , 382, 1485-95	40	180
70	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2013 , 1, 19-27	18.1	32
69	Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 787-96	6.9	45
68	Community-Based Screening for Chronic Kidney Disease, Hypertension and Diabetes in Dharan. <i>Journal of the Nepal Medical Association</i> , 2013 , 52, 205-212	0.4	25
67	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. <i>Blood</i> , 2012 , 119, 3269-75	2.2	90
66	Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1717-24	12.7	65
65	Rituximab in idiopathic membranous nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1416-25	12.7	187
64	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. <i>Journal of Transplantation</i> , 2012 , 2012, 426042	2.3	8
63	Sodium intake, ACE inhibition, and progression to ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 165-73	12.7	216
62	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. <i>BMJ Open</i> , 2012 , 2,	3	29
61	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011 , 79, 1331-40	9.9	468
60	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. <i>Journal of Hypertension</i> , 2011 , 29, 207-16	1.9	53
59	Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic telangiectasia. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2166-78	4	89
58	Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1923-30	12.7	167
57	Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. <i>Hypertension</i> , 2011 , 58, 776-83	8.5	75
56	ACE inhibition is renoprotective among obese patients with proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1122-8	12.7	84
55	The Remission Clinic approach to halt the progression of kidney disease. <i>Journal of Nephrology</i> , 2011 , 24, 274-81	4.8	13
54	Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial. <i>Journal of Ophthalmology</i> , 2010 , 2010, 106384	2	14

53	Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 1928-38	6.9	31
52	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial: Response to Sarigianni, Katsiki, and Mikhailidis. <i>Diabetes Care</i> , 2010 , 33, e133-e133	14.6	
51	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 695-703	13.9	15
50	Outcome of renal transplantation from very old donors. <i>New England Journal of Medicine</i> , 2009 , 360, 1464-5	59.2	24
49	Mycophenolate mofetil versus azathioprine in organ transplantation. <i>American Journal of Transplantation</i> , 2009 , 9, 2856-7	8.7	12
48	Role of remission clinics in the longitudinal treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 1213-24	12.7	158
47	Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). <i>Diabetes Care</i> , 2008 , 31, 1629-34	14.6	30
46	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. <i>The Cochrane Library</i> , 2008 , CD003233	5.2	29
45	Long-term outcome of renal transplantation from older donors. <i>New England Journal of Medicine</i> , 2006 , 354, 343-52	59.2	370
44	Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, 3472-81	12.7	54
43	Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 546-54	6.9	34
42	Rituximab for idiopathic membranous nephropathy: who can benefit?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 738-48	6.9	69
41	Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. <i>Liver International</i> , 2006 , 26, 1040-6	7.9	104
40	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. <i>Lancet, The</i> , 2005 , 365, 939-46	40	471
39	Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005 , 6, 16		23
38	Preventing microalbuminuria in type 2 diabetes. <i>New England Journal of Medicine</i> , 2005 , 352, 833-4; author reply 833-4	59.2	4
37	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005 , 2, 95-105		
36	Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 3117-25	12.7	88

35	Preventing microalbuminuria in type 2 diabetes. <i>New England Journal of Medicine</i> , 2004 , 351, 1941-51	59.2	790
34	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. <i>Cochrane Database of Systematic Reviews</i> , 2004 , CD004293		22
33	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. <i>American Journal of Kidney Diseases</i> , 2004 , 44, 385-401	7.4	77
32	Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. <i>American Journal of Kidney Diseases</i> , 2004 , 44, 385-401	7.4	32
31	Rituximab in idiopathic membranous nephropathy: a one-year prospective study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1851-7	12.7	169
30	The BERgamo NEphrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2003 , 24, 442-61		32
29	Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study. <i>Leukemia Research</i> , 2003 , 27, 763-4	2.7	2
28	Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. <i>Kidney International</i> , 2003 , 63, 2254-61	9.9	187
27	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. <i>Kidney International</i> , 2003 , 63, 1094-103	9.9	140
26	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. <i>Kidney International</i> , 2003 , 63, 1924-33	9.9	6
25	Nonimmunosuppressive therapy of membranous nephropathy. <i>Seminars in Nephrology</i> , 2003 , 23, 333-9	4.8	13
24	Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. <i>Circulation</i> , 2003 , 107, 586-92	16.7	54
23	Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model. <i>Nephron Clinical Practice</i> , 2003 , 95, c47-59		4
22	Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 755-66	12.7	23
21	More concern about transfusion requirement when evaluating quality of life in anemic patients. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3182-3; author reply 3183-4	2.2	16
20	Single Strand Conformation Polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. <i>Clinical Biochemistry</i> , 2002 , 35, 363-8	3.5	12
19	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. <i>Lancet, The</i> , 2002 , 359, 663-6	40	86
18	ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2001 , 12, 2832-2837	12.7	150

17	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies ¹ . <i>Kidney International</i> , 2000 , 57, 274-81	9.9	64
16	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group. <i>Kidney International</i> , 2000 , 58, 2093-101	9.9	8
15	Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. <i>American Journal of Kidney Diseases</i> , 2000 , 35, 1155-65	7.4	147
14	Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemiologici in Nefrologia (Gisen). <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, 88-96	12.7	72
13	Non-diabetic nephropathies and ACE inhibition. <i>Lancet, The</i> , 1999 , 354, 1905-6	4.0	0
12	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <i>Lancet, The</i> , 1999 , 354, 359-64	4.0	657
11	In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 997-1006	12.7	128
10	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). <i>Kidney International</i> , 1998 , 53, 1209-16	9.9	309
9	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. <i>Lancet, The</i> , 1998 , 352, 1252-6	4.0	443
8	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. <i>BMJ: British Medical Journal</i> , 1998 , 316, 504-9		173
7	Recent developments in the management of membranous nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 1997 , 6, 521-32	5.9	6
6	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. <i>Lancet, The</i> , 1997 , 349, 1857-1863	4.0	1475
5	Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. <i>Transplantation</i> , 1997 , 63, 1508-14	1.8	45
4	Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 34-41	7.4	43
3	Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. <i>American Journal of Kidney Diseases</i> , 1993 , 22, 264-6	7.4	40
2	Prognosis of untreated patients with idiopathic membranous nephropathy. <i>New England Journal of Medicine</i> , 1993 , 329, 85-9	59.2	284
1	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. <i>Kidney International</i> , 1992 , 42, 981-90	9.9	17